GlassScriptPhysician profile
Angela P Reed
NPI 1841766656
$1,188.22
in general payments reported to CMS, 2019-2025
17 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $281 · 2022: $84.83 · 2023: $253 · 2024: $267 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $302.87 | 2021-2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $127.42 | 2021-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $123.52 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $96.45 | 2024-2025 | |
| Ardelyx, INC. | $89.87 | 2025 | Ibsrela |
| Abbvie INC. | $85.78 | 2021-2023 | |
| Amgen INC. | $67.45 | 2021-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $64.33 | 2023-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $59.95 | 2021-2024 | |
| Corcept Therapeutics | $37.81 | 2024 | Korlym |
| Microtransponder, INC. | $26.18 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.81 | 2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.42 | 2021 | |
| Amarin Pharma, INC. | $18.66 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.68 | 2024 | Voquezna |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $15.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.55 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.